Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Clinical trial NCT03558087 · COMPLETED
Trial details
- NCT number
- NCT03558087
- Sponsor
- Matthew Galsky
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-13
- Primary completion
- 2024-02-16
- Enrollment
- 76
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.